(NASDAQ: CMRX) Chimerix's forecast annual revenue growth rate of 638.06% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.19%.
Chimerix's revenue in 2024 is $159,000.On average, 3 Wall Street analysts forecast CMRX's revenue for 2024 to be $869,951,441, with the lowest CMRX revenue forecast at $11,601,751, and the highest CMRX revenue forecast at $2,586,560,884. On average, 2 Wall Street analysts forecast CMRX's revenue for 2025 to be $410,558,082, with the lowest CMRX revenue forecast at $11,691,687, and the highest CMRX revenue forecast at $809,424,477.
In 2026, CMRX is forecast to generate $6,991,628,760 in revenue, with the lowest revenue forecast at $1,261,802,824 and the highest revenue forecast at $12,721,454,697.